文献速递卫生政策与健康促进免疫规划

推进非洲本地疫苗生产能力——机遇、优先事项与挑战

Advancing local manufacturing capacities for vaccines within Africa - Opportunities, priorities and challenges.
PubMed 文献 · Vaccine · 2025-02-05

非洲占全球疫苗使用总量的25%,但其中99%的疫苗在海外生产。本文检视非洲现有疫苗生产能力、优先疫苗需求及推进本地生产的机遇与挑战。非洲11家生产商中10家具备制剂/灌装/包装能力,仅南非和塞内加尔具备端到端生产能力;确定麻疹-风疹、黄热病、霍乱、轮状病毒和脑膜炎球菌疫苗为本地生产前5位优先疫苗。

要点

  • 非洲占全球疫苗使用量25%,但99%的疫苗在海外生产。
  • 非洲11家生产商中10家具备制剂/灌装/包装能力,仅南非和塞内加尔具备端到端生产能力。
  • 本地生产前5位优先疫苗为麻疹-风疹、黄热病、霍乱、轮状病毒和脑膜炎球菌疫苗。

核心结论

  • 非洲疫苗生产商和所有利益相关方应着力推进非洲大陆疫苗生产所需的一系列活动,包括监管能力强化、培训和劳动力发展,而非仅关注有利于某一生产商或国家的努力。

研究设计与样本

  • 本文为观点文章,聚焦非洲占全球疫苗使用总量25%而其中99%在海外生产的矛盾,回顾非洲现有疫苗生产能力、优先疫苗需求及推进本地生产的机遇与挑战。

主要发现

  • 非洲11家生产商中10家具备制剂/灌装/包装能力,但本地生产活性疫苗组分的能力非常有限。
  • 利用活减毒病毒、灭活病毒和mRNA等疫苗技术平台的情况仍然很少。
  • 南非和塞内加尔是仅有的具备端到端生产能力的国家。
  • 基于市场需求、生产复杂性、目标人群、疾病负担和接种方案,确定非洲本地生产前5位优先疫苗为麻疹-风疹、黄热病、霍乱、轮状病毒和脑膜炎球菌疫苗。

关键数值与推荐

  • 非洲疫苗生产倡议的使能因素包括:通过GAVI和UNICEF对非洲产疫苗的优先采购以确保可持续和可靠的数量;交易准备以定向投资避免生产过剩;技术转让;监管体系强化;研发能力和基础设施。
  • 2023年12月GAVI宣布建立非洲疫苗生产加速器,这是一项10亿美元的融资机制,旨在非洲创建可持续的疫苗生产产业。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出许多挑战需要克服,包括为维持已开发成果获得可靠资金。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our viewpoint focuses on the paradox that Africa represents 25 % of total global vaccine usage, yet 99 % of these vaccines are manufactured overseas. In view of the iniquitous supply and distribution of COVID-19 vaccines to Africa during the pandemic, we emphasize the need for scaling up local vaccine manufacturing capacities across Africa. We review current vaccine manufacturing capacities within Africa, highlight priority vaccines needs, and describe opportunities and challenges of advancing local manufacturing capacities within Africa. Of 11 manufacturers in Africa, ten have operational formulation/fill/finish capacities. However, capacities to produce active vaccine components locally are very limited and leveraging of vaccine technology platforms such as live-attenuated virus, inactivated virus, and mRNA remain scanty. South Africa and Senegal are the only countries with end-to-end manufacturing capacities. Based on market demand, manufacturing complexity, target population, disease burden and vaccination regimen, the top 5 priority vaccines identified for local manufacturing in Africa were measles-rubella, yellow fever, cholera, rotavirus, and meningococcal vaccines. Enablers identified for Africa's vaccine manufacturing initiatives include: a preferential procurement of African-made vaccines for sustainable and reliable volumes through GAVI and UNICEF; deal preparation to target investments avoiding overproduction; technology transfers; regulatory systems strengthening; R&D capacities and infrastructure. Thus, African vaccine manufacturers and all stakeholders should focus taking forward the portfolio of activities required for continental vaccine manufacturing, including regulatory strengthening capacities, training and workforce development, rather than only focus on efforts that benefit a particular manufacturer or country. Optimism for advancing vaccine manufacturing in Africa comes from the announcement in December 2023 by GAVI for the establishment of the African Vaccine Manufacturing Accelerator, a financing mechanism of USD 1 billion aimed at creating a sustainable vaccine manufacturing industry in Africa. However, many challenges need to be overcome including that of having secure funding for sustaining what is developed.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Doua J, Ndembi N, Auerbach J, et al. Advancing local manufacturing capacities for vaccines within Africa - Opportunities, priorities and challenges. Vaccine. 2025. PMID: 39914258. doi:10.1016/j.vaccine.2025.126829

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。